Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Phase 2 trialsStub

Eloralintide

Long-acting amylin receptor agonist

A once-weekly amylin receptor agonist with published phase 2 results in obesity.

Reconstitution calculator

At a glance

Phase 2 trials

Mid-sized trials in people have measured dose and effect. It is not a licensed medicine.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2: Eloralintide

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

10
papers on PubMed
7
of them in people
3
randomized trials
6
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Eloralintide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Eloralintide; no amount here is a recommendation.

Eloralintide: on PubMed

What PubMed held for Eloralintide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

10
papers
7
in humans
3
clinical trials
3
randomized trials
2012: 0 papers122013: 0 papers2014: 0 papers142015: 0 papers2016: 0 papers162017: 0 papers2018: 0 papers182019: 0 papers2020: 0 papers202021: 0 papers2022: 0 papers222023: 0 papers2024: 0 papers242025: 2 papers2026: 8 papers so far26
Papers per year, 2012 to 2026. The most in one year: 8.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

    Randomized trialBriere DA, Qu H, Lansu K, et al. Molecular metabolism, 2025. PMID 41109426

  2. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

    Randomized trialBillings LK, Hsia S, Bays H, et al. Lancet (London, England), 2025. PMID 41207310

  3. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

    Randomized trialBhattachar S, Tham LS, Tidemann-Miller B, et al. Diabetes, obesity & metabolism, 2026. PMID 41559929

  4. Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis

    ReviewKamrul-Hasan ABM, Khalil I, Mahajan K, et al. Endocrinology, diabetes & metabolism, 2026. PMID 42175595

  5. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes

    ReviewBailey CJ, Flatt PR, Conlon JM Peptides, 2026. PMID 41747885

  6. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus

    ReviewPanou T, Gouveri E, Popovic DS, et al. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID 42803913

  7. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials

    ReviewAlhazmi A, le Roux CW Diabetes, obesity & metabolism, 2026. PMID 42452898

  8. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs

    ReviewFischer SL, Borner T Pharmacological research, 2026. PMID 42586227

Search used: ("Eloralintide"[tiab]). Run it on PubMed

Research links

Also in Metabolic